International Journal of Cardiology: Hypertension最新文献

{"title":"The effect of remote ischaemic conditioning on blood pressure response: A systematic review and meta-analysis","authors":"Biggie Baffour-Awuah ,&nbsp;Gudrun Dieberg ,&nbsp;Melissa J. Pearson ,&nbsp;Neil A. Smart","doi":"10.1016/j.ijchy.2021.100081","DOIUrl":"10.1016/j.ijchy.2021.100081","url":null,"abstract":"<div><h3>Background</h3><p>Previous work has evaluated the effect of remote ischaemic conditioning (RIC) in a number of clinical conditions (e.g. cardiac surgery and acute kidney injury), but only one analysis has examined blood pressure (BP) changes. While individual studies have reported the effects of acute bouts and repeated RIC exposure on resting BP, efficacy is equivocal. We conducted a systematic review and meta-analysis to evaluate the effects of acute and repeat RIC on BP.</p></div><div><h3>Methods</h3><p>A systematic search was performed using PubMed, Web of Science, EMBASE, and Cochrane Library of Controlled Trials up until October 31, 2020. Additionally, manual searches of reference lists were performed. Studies that compared BP responses after exposing participants to either an acute bout or repeated cycles of RIC with a minimum one-week intervention period were considered.</p></div><div><h3>Results</h3><p>Eighteen studies were included in this systematic review, ten examined acute effects while eight investigated repeat effects of RIC. Mean differences (MD) for outcome measures from acute RIC studies were: systolic BP 0.18 mmHg (95%CI -0.95, 1.31; <em>p</em> = 0.76), diastolic BP -0.43 mmHg (95%CI -2.36, 1.50; <em>p</em> = 0.66), MAP -1.73 mmHg (95%CI -3.11, −0.34; <em>p</em> = 0.01) and HR -1.15 bpm (95%CI -2.92, 0.62; <em>p</em> = 0.20). Only MAP was significantly reduced. Repeat RIC exposure showed non-significant change in systolic BP -3.23 mmHg (95%CI -6.57, 0.11; <em>p</em> = 0.06) and HR -0.16 bpm (95%CI -7.08, 6.77; <em>p</em> = 0.96) while diastolic BP -2.94 mmHg (95%CI -4.08, −1.79; <em>p</em> &lt; 0.00001) and MAP -3.21 mmHg (95%CI -4.82, −1.61; <em>p</em> &lt; 0.0001) were significantly reduced.</p></div><div><h3>Conclusions</h3><p>Our data suggests repeated, but not acute, RIC produced clinically meaningful reductions in diastolic BP and MAP.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"8 ","pages":"Article 100081"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2021.100081","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25502352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring blood pressure by a cuffless device using the pulse transit time","authors":"Andreas Patzak","doi":"10.1016/j.ijchy.2020.100072","DOIUrl":"10.1016/j.ijchy.2020.100072","url":null,"abstract":"","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"8 ","pages":"Article 100072"},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38897122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term BP variability: open questions in clinical practice","authors":"Rita Del Pinto,&nbsp;Claudio Ferri","doi":"10.1016/j.ijchy.2020.100064","DOIUrl":"10.1016/j.ijchy.2020.100064","url":null,"abstract":"","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100064"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38824642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interamerican Society of Cardiology (IASC) position statement: Chlorthalidone vs. thiazide-type diuretics","authors":"Anil Pareek,&nbsp;Franz H. Messerli,&nbsp;Gustavo Saravia,&nbsp;Ravi Tejraj Mehta","doi":"10.1016/j.ijchy.2020.100054","DOIUrl":"10.1016/j.ijchy.2020.100054","url":null,"abstract":"<div><p>The Interamerican Society of Cardiology (IASC) Position Statement for hypertension management in Latin America is a practical and useful review of five different hypertension guidelines. Though, thiazide diuretics have been recommended as firstline option, the position statement needs to highlight differences <em>within</em> the thiazide class. Chlorthalidone is structurally and pharmacokinetically distinct from thiazide-<em>type</em> iuretics like hydrochlorothiazide with a longer half-life and 24-h anti-hypertensive effect. It has been shown to reduce cardiovascular morbidity and mortality in several landmark studies evaluating anti-hypertensives.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100054"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38821497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic lupus erythematosus and cardiovascular disease","authors":"Luis M. Ruilope,&nbsp;G. Ruiz-Hurtado","doi":"10.1016/j.ijchy.2020.100065","DOIUrl":"10.1016/j.ijchy.2020.100065","url":null,"abstract":"","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100065"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38824643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erythrocyte metabolism, oxygen delivery, and hypertensive kidney disease","authors":"Ulrich Limper,&nbsp;Jens Tank,&nbsp;Jens Jordan","doi":"10.1016/j.ijchy.2020.100049","DOIUrl":"10.1016/j.ijchy.2020.100049","url":null,"abstract":"","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100049"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100049","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38821495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age and blood pressure goal in women with prior coronary events","authors":"Luis M. Ruilope,&nbsp;Gema Ruiz-Hurtado","doi":"10.1016/j.ijchy.2020.100059","DOIUrl":"10.1016/j.ijchy.2020.100059","url":null,"abstract":"","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100059"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38824637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVEST☆","authors":"Ruxandra I. Sava ,&nbsp;Steven M. Smith ,&nbsp;Yiqing Chen ,&nbsp;Yasmeen Taha ,&nbsp;Yan Gong ,&nbsp;Ellen C. Keeley ,&nbsp;Rhonda M. Cooper-Dehoff ,&nbsp;Carl J. Pepine ,&nbsp;Eileen M. Handberg","doi":"10.1016/j.ijchy.2020.100052","DOIUrl":"10.1016/j.ijchy.2020.100052","url":null,"abstract":"<div><h3>Background</h3><p>Hypertension and coronary artery disease (CAD) are a prevalent combination in older women, however limited data are available to guide blood pressure (BP) management. We hypothesized that older women with hypertension and CAD may not derive long-term benefit by achieving systolic BP (SBP) &lt; 130 mmHg.</p></div><div><h3>Methods</h3><p>We analyzed long-term all-cause mortality data from the International Verapamil SR/Trandolapril Study (INVEST), stratified by risk attributable to clinical severity of CAD (women with prior coronary events of myocardial infarction or revascularization considered high risk, all others at low risk) and by age group (50–64 or ≥65 years). The prognostic impact of achieving mean in-trial SBP &lt;130 (referent group) was compared with 130–139 and ≥ 140 mmHg using Cox proportional hazards, adjusting for demographic and clinical characteristics.</p></div><div><h3>Results</h3><p>SBPs &lt;130, 130–139, and ≥140 were achieved in 2960, 3024, and 3232 women, respectively. Among high-risk women aged ≥65 years, those achieving SBP 130–139 mmHg had lower mortality up to 16.7 years later than those with SBP &lt;130 (hazard ratio [HR] 0.81, 95% CI 0.69–0.96). High-risk women aged 50–64 achieving SBP 130–139 had a similar mortality risk as those with SBP &lt;130 (HR 1.21, 95% CI 0.87–1.68), while those achieving SBP ≥140 mmHg had a higher mortality risk than SBP &lt; 130 (HR 1.92, 95% CI 1.37–2.68). A similar pattern was observed among low-risk women ≥65 and &lt;65 years old.</p></div><div><h3>Conclusion</h3><p>Among women ≥65 years old with hypertension and prior coronary events, in-trial SBP between 130 and 139 mmHg was associated with lower mortality over the long term versus SBP &lt;130 mmHg.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25576093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension and the roles of the 9p21.3 risk locus: Classic findings and new association data","authors":"Juan E. Gallo ,&nbsp;Juan E. Ochoa ,&nbsp;Helen R. Warren ,&nbsp;Elizabeth Misas ,&nbsp;Monica M. Correa ,&nbsp;Jaime A. Gallo-Villegas ,&nbsp;Gabriel Bedoya ,&nbsp;Dagnóvar Aristizábal ,&nbsp;Juan G. McEwen ,&nbsp;Mark J. Caulfield ,&nbsp;Gianfranco Parati ,&nbsp;Oliver K. Clay","doi":"10.1016/j.ijchy.2020.100050","DOIUrl":"10.1016/j.ijchy.2020.100050","url":null,"abstract":"<div><h3>Background</h3><p>The band 9p21.3 contains an established genomic risk zone for cardiovascular disease (CVD). Since the initial 2007 Wellcome Trust Case Control Consortium study (WTCCC), the increased CVD risk associated with 9p21.3 has been confirmed by multiple studies in different continents. However, many years later there was still no confirmed report of a corresponding association of 9p21.3 with hypertension, a major CV risk factor, nor with blood pressure (BP).</p></div><div><h3>Theory</h3><p>In this contribution, we review the bipartite haplotype structure of the 9p21.3 risk locus: one block is devoid of protein-coding genes but contains the lead CVD risk SNPs, while the other block contains the first exon and regulatory DNA of the gene for the cell cycle inhibitor p15. We consider how findings from molecular biology offer possibilities of an involvement of p15 in hypertension etiology, with expression of the p15 gene modulated by genetic variation from within the 9p21.3 risk locus.</p></div><div><h3>Results</h3><p>We present original results from a Colombian study revealing moderate but persistent association signals for BP and hypertension within the classic 9p21.3 CVD risk locus. These SNPs are mostly confined to a ‘hypertension island’ that spans less than 60 kb and coincides with the p15 haplotype block. We find confirmation in data originating from much larger, recent European BP studies, albeit with opposite effect directions.</p></div><div><h3>Conclusion</h3><p>Although more work will be needed to elucidate possible mechanisms, previous findings and new data prompt reconsidering the question of how variation in 9p21.3 might influence hypertension components of cardiovascular risk.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100050"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100050","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38733230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of advanced statistical techniques to predict all-cause mortality in the Systolic Blood Pressure Intervention Trial","authors":"William J. Kostis ,&nbsp;Javier Cabrera ,&nbsp;Chun Pang Lin ,&nbsp;John B. Kostis ,&nbsp;Jennifer Wellings ,&nbsp;Stavros Zinonos ,&nbsp;Jeanne M. Dobrzynski ,&nbsp;Daniel Blickstein","doi":"10.1016/j.ijchy.2020.100053","DOIUrl":"10.1016/j.ijchy.2020.100053","url":null,"abstract":"<div><h3>Background</h3><p>The Systolic Blood Pressure Intervention Trial (SPRINT) was conducted in patients with hypertension and additional risk for cardiovascular disease who were randomized to the intensive blood pressure group targeting systolic blood pressure (SBP) less than 120 mm Hg and to the standard group where the target was less than 140 mm Hg. Analyses were done in the matched group of participants with the same gender, same age (±2 years) and same SBP (±3 mm Hg) at three months of treatment regardless of initial randomization to intensive or standard group (shaded area in Figure 1).</p></div><div><h3>Methods and results</h3><p>During 3.26 years of follow-up, intensive group participants had 14.8 mm Hg lower SBP and received on average one more (2.8 vs. 1.8) blood pressure lowering medications. This was associated with lower all-cause mortality in the intensive treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90, p = 0.003). The effect on SBP was achieved at 3 months and remained unchanged thereafter. This paper addresses two questions with respect to all-cause mortality in SPRINT in the matched set. 1) What is the effect of receiving more than one drug on all-cause mortality. Conditional logistic regression for all-cause mortality with respect to number of drugs indicated that during the 3.26 years of follow-up persons who received more than one drug were more likely to die (coefficient = 0.5039, OR = 1.6552, p = 0.0322) than patients who received one drug. 2) Was there a U curve relationship between on treatment SBP and all-cause mortality? A U curve fitting a quadratic equation (parabola) of SBP and all-cause death was observed. This was seen in the patients randomized to the standard target group in unadjusted analyses as well as in analyses adjusted for demographics or all covariates (p &lt; 0.001 for all). The U curves in the combined group and the intensive treatment group were less pronounced.</p></div><div><h3>Conclusion</h3><p>SPRINT participants who were matched for gender, age, and SBP at 3 months, and received more than one drug had higher all-cause mortality during the 3.26 years of follow-up. Those who were randomized to standard treatment target had a U curve relationship between SBP at three months and all-cause mortality. The U curves in the combined group and the intensive treatment group were less pronounced.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"7 ","pages":"Article 100053"},"PeriodicalIF":0.0,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2020.100053","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38821496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}